Human papillomavirus vaccine - Oryx

Drug Profile

Human papillomavirus vaccine - Oryx

Alternative Names: P16_37-63; p16INK4a peptide vaccine; p16INK4a-37-63; Vaccine p16; VicOryx

Latest Information Update: 13 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Heidelberg
  • Developer Oryx GmbH & Co
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Cyclin-dependent kinase inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Cancer

Most Recent Events

  • 01 May 2017 Oryx GmbH completes a phase I/IIa trial in Cancer (Late-stage disease, Combination therapy) in Germany (NCT02526316) (Oryx pipeline, August 2017)
  • 07 Jan 2016 Human papillomavirus vaccine is available for licensing before Jan 2016.
  • 15 Sep 2015 Efficacy data from a phase I/II trial in Cancer released by Oryx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top